---
title: >-
  The Liver Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD,
  MSCR
description: >-
  Read the latest news on regulatory-grade real-world evidence: The Liver
  Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR.
date: '2024-12-04'
category: News
tags:
  - Conference Presentation
  - R&D
  - Care
  - Cross-cutting
  - General
canonical_url: >-
  https://www.pedestalhealth.com/resources/news/conference-presentation/the-liver-meeting-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: the-liver-meeting-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr
id: 38XNVWiCfpjEtbJcbsylIj
contentType: article
---

Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study at The Liver Meeting 2024 titled, *“Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.”*

The study analyzed data from a real-world cohort of MASLD patients and found that those taking GLP-1 RAs had a significantly lower risk of death and progression to a more severe form of liver disease compared to non-users. Learn more about the impact of GLP-1 RAs on MASLD patient outcomes in this insightful presentation by Dr. Barritt.